{
  "variants": [
    {
      "gene": "DJ1",
      "variant": "c.192G>C (p.E64D)",
      "description": "A mutation in the DJ1 gene associated with early-onset Parkinson's disease (EOPD).",
      "functional_evidence": [
        {
          "method": "PET imaging",
          "finding": "Reduced dopamine transporter (DAT) binding in the striatum, indicating impaired dopamine signaling."
        },
        {
          "method": "Cell culture",
          "finding": "Decreased levels of the mutant protein when overexpressed in HEK293 and COS7 cells."
        },
        {
          "method": "Immunocytochemistry",
          "finding": "Nuclear localization of the mutant protein in 5% of cells, compared to cytoplasmic localization in wild-type controls."
        },
        {
          "method": "Crystallography",
          "finding": "No structural changes in the DJ1 protein, suggesting the mutation does not disrupt the protein's 3D structure."
        }
      ],
      "clinical_context": "Homozygous in a patient's sister (clinically unaffected), while a heterozygous brother showed reduced DAT binding compared to wild-type controls."
    }
  ],
  "analysis": {
    "variant_evidence": [
      {
        "variant": "c.192G>C (p.E64D)",
        "acmg_steps": [
          {
            "step": "1. Disease mechanism",
            "finding": "DJ1 mutations are causally linked to EOPD, with functional assays targeting dopamine pathways and protein localization."
          },
          {
            "step": "2. Assay applicability",
            "finding": "PET (DAT binding), crystallography, and cell culture assays are directly relevant to the disease mechanism."
          },
          {
            "step": "3. Validity of assays",
            "finding": "Controls (wild-type vs. mutant, heterozygous vs. homozygous) are present. Overexpression studies include variant controls."
          },
          {
            "step": "4. Statistical analysis",
            "finding": "No OddsPath calculation, but controls (e.g., heterozygous brother, homozygous sister) are present. Total variant controls >10."
          }
        ],
        "strength": "PS3_moderate",
        "rationale": "Functional evidence includes reduced DAT binding, altered protein localization, and decreased protein levels. Crystallography shows no structural change, but functional assays indicate pathogenicity. No OddsPath calculation, but sufficient controls for moderate strength."
      }
    ],
    "variant_without_evidence": [
      {
        "variant": "L166P (DJ1)",
        "reason": "No functional evidence is provided in the text. The mutation is described as 'recently described' but lacks experimental validation."
      }
    ]
  }
}